Journal articleThe Journal of surgical research · April 2019
BackgroundThe emergence of immune checkpoint inhibitors (ICIs) has improved survival for patients with metastatic melanoma. The types of disease-response patterns to ICI therapy can be more complex relative to traditional chemotherapy and include ...
Full textCite